

BROMFENAC SODIUM- bromfenac sodium solution/ drops

Lupin Pharmaceuticals, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BROMFENAC OPHTHALMIC SOLUTION 0.07% safely and effectively.

See full prescribing information for BROMFENAC OPHTHALMIC SOLUTION.

BROMFENAC ophthalmic solution 0.07%

Initial U.S. Approval: 1997

INDICATIONS AND USAGE

Bromfenac ophthalmic solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. (1)

DOSAGE AND ADMINISTRATION

Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-surgery. (2.1)

DOSAGE FORMS AND STRENGTHS

Ophthalmic solution: bromfenac 0.07 % (3)

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

- Sulfite Allergic Reactions (5.1)
- Slow or Delayed Healing (5.2)
- Potential for cross-sensitivity (5.3)
- Increase bleeding Time (5.4)
- Keratitis and Corneal Reactions (5.5)

ADVERSE REACTIONS

The most commonly reported adverse reactions in 3 to 8 % of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

2.2 Use with Other Topical Ophthalmic Medications

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Sulfite Allergic Reactions

5.2 Slow or Delayed Healing

5.3 Potential for Cross-Sensitivity

5.4 Increased Bleeding Time

5.5 Keratitis and Corneal Reactions

5.6 Risk of Contamination

5.7 Contact Lens Wear

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Ocular Inflammation and Pain

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Bromfenac ophthalmic solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

Apply one drop to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.

2.2 Use with Other Topical Ophthalmic Medications

Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

3 DOSAGE FORMS AND STRENGTHS

Ophthalmic solution: bromfenac 0.07 %

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 Sulfite Allergic Reactions

Bromfenac ophthalmic solution contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

5.2 Slow or Delayed Healing

All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

5.3 Potential for Cross-Sensitivity

There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

5.4 Increased Bleeding Time

With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

5.5 Keratitis and Corneal Reactions

Use of topical NSAIDs, including bromfenac, may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health.

Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse

events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

5.6 Risk of Contamination

Do not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the contents. Replace the bottle cap after using.

5.7 Contact Lens Wear

Bromfenac ophthalmic solution should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution.

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions following use of bromfenac ophthalmic solution following cataract surgery include: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. These reactions were reported in 3 to 8 % of patients.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on bromfenac ophthalmic solution use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

The systemic exposure to bromfenac following topical ocular administration is low [see Clinical Pharmacology (12.3)]. Consequently, the systemic exposure of a pregnant woman to bromfenac is expected to be minimal following topical ocular administration.

However, because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or

other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Premature closure of the ductus arteriosus in the fetus has occurred with third trimester use of oral and injectable NSAIDs. Measurable maternal and fetal plasma drug levels are available with oral and injectable routes of NSAID administration. The maternal plasma level of Bromfenac ophthalmic solution following ocular administration is unknown [see Clinical Pharmacology (12.3)].

Data

Animal Data

Embryo-fetal lethality and maternal toxicity were produced in rats and rabbits treated with bromfenac during the period of organogenesis at oral doses up to 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. These doses corresponded to a C_{max} 90- and 150-times the predicted C_{max} at the recommended human ophthalmic dose (RHOD), respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human C_{max} at the RHOD), and caused dystocia, increased neonatal mortality, and reduced postnatal growth at 0.9 mg/kg/day (90 times the predicted human C_{max} at the RHOD).

8.2 Lactation

There are no data on the presence of bromfenac in human milk, the effects on the breastfed infant, or the effects on milk production.

The systemic exposure of a breastfeeding woman to bromfenac is expected to be minimal following topical ocular administration, however, the possibility of harm to the breastfed infant cannot be ruled out.

The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for bromfenac ophthalmic solution, and any potential adverse effects on the breastfed infant from bromfenac ophthalmic solution or from the underlying maternal conditions.

8.4 Pediatric Use

The safety and effectiveness of bromfenac ophthalmic solution have not been established in pediatric patients.


8.5 Geriatric Use

No overall differences in safety or effectiveness of bromfenac ophthalmic solution have been observed between patients 70 years of age and older and younger adult patients.

11 DESCRIPTION

Bromfenac ophthalmic solution 0.07 % is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for topical ophthalmic use. Each mL of bromfenac ophthalmic solution contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac

free acid). The USAN name for bromfenac sodium sesquihydrate is bromfenac sodium. Bromfenac sodium is designated chemically as sodium [2-amino-3-(4-bromobenzoyl) phenyl] acetate sesquihydrate, with a molecular formula of $C_{15}H_{11}BrNNaO_3 \cdot 1\frac{1}{2}H_2O$. The chemical structure for bromfenac sodium sesquihydrate is:



Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac ophthalmic solution, 0.07 % is supplied as a sterile aqueous 0.07 % solution, with a pH of 7.55 to 8.15. The osmolality of bromfenac ophthalmic solution, 0.07 % is approximately 280 to 340 mOsmol/kg.

Each mL of bromfenac ophthalmic solution, 0.07 % contains:

Active: Each mL contains bromfenac sodium sesquihydrate 0.0805 %, which is equivalent to bromfenac free acid 0.07 %.

Preservative: benzalkonium chloride 0.005 %

Inactives: boric acid, edetate disodium (dihydrate), povidone, sodium borate, sodium sulfite, sodium hydroxide to adjust pH, tyloxapol and water for injection USP.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

12.3 Pharmacokinetics

The plasma concentration of bromfenac following ocular administration of 0.07 % bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to each eye (0.035 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from RHOD assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively, revealed no significant increases in tumor incidence.

Mutagenesis

Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.

Impairment of Fertility

Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively).

14 CLINICAL STUDIES

14.1 Ocular Inflammation and Pain

Bromfenac 0.07 % QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07 % or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery. Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8 and 15 post-surgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07 % was superior to vehicle as shown in the following table.

Proportion of Subjects with Cleared Ocular Inflammation (0 cells and no flare)				
Study	Visit	Bromfenac 0.07 %	Vehicle	Difference (%) (Asymptotic 95 % CI)
Study 1	At Day 8	27/112 (24.1%)	7/108 (6.5%)	17.6 (8.4, 26.8)
	At Day 15	51/112 (45.5%)	14/108 (13.0%)	32.5 (21.4, 43.8)
Study 2	At Day 8	33/110 (30.0%)	14/110 (12.7%)	17.3 (6.7, 27.9)
	At Day 15	50/110 (45.5%)	30/110 (27.3%)	18.2 (5.7, 30.7)
Proportion of Subjects who Were Pain Free				

Study	Visit	Bromfenac 0.07%	Vehicle	Difference (%) (Asymptotic 95% CI)
Study 1	At Day 1	91/112 (81.3%)	47/108 (43.5%)	37.7 (25.9, 49.6)
Study 2	At Day 1	84/110 (76.4%)	61/110 (55.5%)	20.9 (8.7, 33.1)

16 HOW SUPPLIED/STORAGE AND HANDLING

Bromfenac Ophthalmic Solution, 0.07% is supplied in a white low density polyethylene bottle fitted with a white low density polyethylene nozzle and sealed with grey colored high density polyethylene cap with tamper-evident ring as follows:

- 3 mL in a 5 mL bottle (NDC 68180-433-02)

Storage

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature]. After opening, bromfenac ophthalmic solution 0.07% can be used until the expiration date of the bottle.

17 PATIENT COUNSELING INFORMATION

Slowed or Delayed Healing

Advise patients of the possibility that slow or delayed healing may occur while using NSAIDs.

Risk of Contamination

Advise patients to not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the contents. Advise patients to replace bottle cap after using.

Contact Lens Wear

Advise patients to remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution.

Use with Other Topical Ophthalmic Medications

Advise patients that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.



LUPIN and the  are registered trademarks of Lupin Pharmaceuticals, Inc.

Manufactured for:

Lupin Pharmaceuticals, Inc.

Naples, FL 34108

United States

Manufactured by:

Lupin Limited

Pithampur (M.P.) - 454 775

India

Revised: March 2025

ID: 280121

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Bromfenac Ophthalmic Solution, 0.07 %

3.0 mL in 5 mL bottle (NDC 68180-433-02)

Rx Only

Carton and Container Labels

3 mL
STERILE

Rx only
LUPIN

0.07%

Bromfenac Ophthalmic Solution

ONCE DAILY

NDC 68180-433-02

NDC 68180-433-02
ONCE DAILY

Bromfenac Ophthalmic Solution

0.07%



Rx only
LUPIN
STERILE
3 mL

Each mL of Bromfenac Ophthalmic Solution Contains
Active: bromfenac sodium sesquihydrate 0.0805 % (0.805 mg) equivalent to bromfenac free acid 0.07 % (0.7 mg)

Preservative: benzalkonium chloride 0.005 %

Inactives: boric acid, edetate disodium (dihydrate), povidone, sodium borate, sodium sulfite, sodium hydroxide to adjust pH, tyloxapol and water for injection USP.

This product is sterile when manufactured and should be dispensed in the original unopened container. Instruct patient on precautions to avoid contamination.

Usual Dosage: Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery. See accompanying prescribing information.

Storage: Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature].

KEEP OUT OF REACH OF CHILDREN.

This package is not child resistant.

M.L. No.: 28/6/2010

NDC 68180-433-02
ONCE DAILY

Bromfenac Ophthalmic Solution

0.07%



Rx only
LUPIN
STERILE
3 mL

Manufactured for:
Lupin Pharmaceuticals, Inc.
Naples, FL 34108
United States

Manufactured by:
Lupin Limited
Pithampur (M.P.) 454 775, INDIA.



277231

NO VARNISH ZONE
30 x 34 mm

Batch coding and other details shall be overprinted at plant.



NDC 68180-433-02

**Bromfenac
Ophthalmic
Solution****ONCE DAILY****0.07 %**Manufactured by:
Lupin Limited
Pithampur (M.P.)
454 775, INDIA

M.L.: 28/6/2010



277378

10 x 8 mm

LOT NO.:

EXP:

FOR TOPICAL APPLICATION IN
THE EYE**LUPIN®**Rx only **3 mL**

← 9615

BROMFENAC SODIUM

bromfenac sodium solution/ drops

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:68180-433
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BROMFENAC SODIUM (UNII: 8ECV571Y37) (BROMFENAC - UNII:864P0921DW)	BROMFENAC	0.805 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)	
BORIC ACID (UNII: R57ZHV85D4)	
EDETATE DISODIUM (UNII: 7FLD91C86K)	
POVIDONE (UNII: FZ989GH94E)	
SODIUM BORATE (UNII: 91MBZ8H3QO)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
SODIUM SULFITE (UNII: VTK01UQK3G)	
TYLOXAPOL (UNII: Y27PUL9H56)	
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68180-433-02	1 in 1 CARTON	01/08/2024	

1	3 mL in 1 BOTTLE, DROPPER; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA206027	01/08/2024	

Labeler - Lupin Pharmaceuticals, Inc. (089153071)

Registrant - LUPIN LIMITED (675923163)

Establishment			
Name	Address	ID/FEI	Business Operations
LUPIN LIMITED		863645527	MANUFACTURE(68180-433) , PACK(68180-433)

Revised: 3/2025

Lupin Pharmaceuticals, Inc.